Cenya Imaging is a clinical stage company developing medical imaging agents to track cells in patients and measure the biodistribution and pharmacokinetics of cell therapies.
Cell therapies, in which cells are administered to patients as a treatment, hold tremendous promise for treating many different diseases. However, cell therapies still have a number of hurdles to clear prior to becoming widely deployed. One such hurdle is an inability to measure the pharmacokinetics and biodistribution of cell therapies in patients over extended periods of time.
Cenya solves this problem with its patented BEACONS (beads for contrast enhancement), which label cell therapies to then track and quantify them using medical imaging when administered to patients.
Cenya BEACONS are:
Approved for use in a human clinical trial
Enable quantitation of cells in vivo
Available at GMP or non-GMP grade
Readily fit in existing cell therapy workflows
May be adapted for multimodal imaging
Validated in various in vitro and in vivo models